Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Head and Neck Neoplasms 3Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Tracheal Diseases 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Parathyroid Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Nasopharyngeal Neoplasms 1Mesothelioma 1Lung Neoplasms 1Laryngeal Diseases 1Hyperparathyroidism, Primary 1Esophageal Neoplasms 1Deglutition Disorders 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Adenoid Cystic 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 3tislelizumab 1spartalizumab 1fludarabine phosphate 1bemarituzumab 1Tablets 1Specimen Handling 1Solutions 1Rogaratinib 1Pemetrexed 1Magnetic Resonance Spectroscopy 1Interleukin-13 1IFL protocol 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Cetuximab 1Carboplatin 1Biopsy 1BID protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × Tablets × Head & Neck × Clear all
NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡